Hengrui Pharmaceuticals
Merck Acquires Rights to Hengrui’s Oral Lp(a) Inhibitor in $2B Deal
Merck, Hengrui Pharmaceuticals, HRS-5346, Lp(a) inhibitor, cardiovascular disease, atherosclerosis, licensing agreement
Merck Secures $2B Deal with China’s Hengrui for Novel Heart Drug
Merck, Hengrui Pharmaceuticals, HRS-5346, Lipoprotein(a) inhibitor, cardiovascular disease, licensing agreement
Hengrui and Kailera’s Obesity Drug HRS9531 Shows Promising Results in Phase 2 Trial
HRS9531, Obesity treatment, GLP-1/GIP receptor dual agonist, Phase 2 clinical trial, Weight loss, Hengrui Pharmaceuticals, Kailera Therapeutics
FDA Rejects Elevar and Hengrui Pharma’s Combination Therapy for Liver Cancer
FDA, Elevar Therapeutics, Hengrui Pharmaceuticals, liver cancer, combination therapy, rejection, clinical trials.